Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts

Yuxin Chu¹,², Cheng Zhang², Min Xie¹,*
¹Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States
²The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, the State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital of Shandong University, Jinan, China

Abstract

One of the characteristics of the failing human heart is a significant alteration in its energy metabolism. Recently, a ketone body, β-hydroxybutyrate (β-OHB) has been implicated in the failing heart’s energy metabolism as an alternative “fuel source.” Utilization of β-OHB in the failing heart increases, and this serves as a “fuel switch” that has been demonstrated to become an adaptive response to stress during the heart failure progression in both diabetic and non-diabetic patients. In addition to serving as an alternative “fuel,” β-OHB represents a signaling molecule that acts as an endogenous histone deacetylase (HDAC) inhibitor. It can increase histone acetylation or lysine acetylation of other signaling molecules. β-OHB has been shown to decrease the production of reactive oxygen species and activate autophagy. Moreover, β-OHB works as an NLR family pyrin domain-containing protein 3 (Nlrp3) inflammasome inhibitor and reduces Nlrp3-mediated inflammatory responses. It has also been reported that β-OHB plays a role in transcriptional or post-translational regulations of various genes’ expression. Increasing β-OHB levels prior to ischemia/reperfusion injury results in a reduced infarct size in rodents, likely due to the signaling function of β-OHB in addition to its role in providing energy. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to exert strong beneficial effects on the cardiovascular system. They are also capable of increasing the production of β-OHB, which may partially explain their clinical efficacy. Despite all of the beneficial effects of β-OHB, some studies have shown detrimental effects of long-term exposure to β-OHB. Furthermore, not all means of increasing β-OHB levels in the heart are equally effective in treating heart failure. The best timing and therapeutic strategies for the delivery of β-OHB to treat heart disease are unknown and yet to

*Correspondence: Min Xie, mxie@uabmc.edu.

AUTHOR CONTRIBUTIONS
YC, CZ, and MX wrote the review article.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fragi.2021.681513/full#supplementary-material

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
be determined. In this review, we focus on the crucial role of ketone bodies, particularly β-OHB, as both an energy source and a signaling molecule in the stressed heart and the overall therapeutic potential of this compound for cardiovascular diseases.

Keywords
β-hydroxybutyrate; HDAC inhibition; ROS; myocardial ischemia/reperfusion injury; heart failure; cardiac metabolism; ketone bodies

INTRODUCTION
The human heart has an exceptionally high metabolic activity as a pump of the body, performing the daily work of circulating 7 tons of blood. It has been reported that the human heart can produce about 6 kg (almost 12 times of its own weight) of ATP daily (Bedi et al., 2016). The high ATP demand for the mechanical and electrical activities of the human heart is almost entirely fulfilled by oxidative phosphorylation, contributing up to 95% of the required ATP production, with the remaining 5% fulfilled by substrate-level phosphorylation in glycolysis (Gibb and Hill, 2018). In the normal adult heart, fatty acids serve as the primary fuel for mitochondrial ATP production, providing 40–70% of the ATP supply, followed by glucose (20–30%), lactate (5–20%), ketones (5–15%), and acetate, pyruvate and branched-chain amino acids (BCAAs) altogether contributing less than 5% to the needed ATP production (Gibb and Hill, 2018).

Ketone bodies, including acetoacetate, β-hydroxybutyrate (β-OHB), and acetone are small molecules synthesized mainly in the hepatic mitochondria and are transported to extrahepatic tissues like the heart, brain, and muscles for oxidation when fatty acid and carbohydrate availability is limited. Acetoacetate and β-OHB are the primary ketone bodies utilized by the heart (Cotter et al., 2013). In a normal fed state, the circulating ketone body concentration is approximately 50 μM. While in neonates, upon fasting, prolonged exercise, or following a ketogenic diet, it can raise up to 1–8 mM (Cahill, 2006; Cotter et al., 2013). In pathological conditions, such as diabetic ketoacidosis, the ketone body concentration can elevate to as high as 20 mM (Cotter et al., 2013) (Figure 1). In diabetes, as well as other disease conditions (e.g. heart failure), ketone body metabolism can also undergo some changes. However, the mechanism of increased ketogenesis during heart failure remains unclear (Aubert et al., 2016; Karwi et al., 2020).

Although most studies focus exclusively on β-OHB, the ketone body metabolism in the heart includes utilization of both β-OHB and acetoacetate, with the ratio of β-OHB to acetoacetate representing the mitochondrial NADH to NAD ratio (Chen et al., 2019). Acetoacetate’s utilization is also increased in diabetic rat hearts (Abdurrachim et al., 2019b), which can enhance contractile function via an anti-oxidation mechanism (Squires et al., 2003). Based on this observation, acetoacetate may serve as a prognostic marker for heart failure. It has been reported that high levels of acetoacetate correlate with increased mortality in patients with heart failure (Yokokawa et al., 2019), which is controversial to its previously reported protective roles. This may be explained by differences in disease states, including factors such as the severity of heart failure and the presence of diabetes.
Moreover, as compared to β-OHB, changes in acetoacetate levels are less affected by stress (Laffel, 1999), suggesting that β-OHB is a more stress-sensitive ketone body. Since the exact mechanism of the cardiac effect of acetoacetate is less well defined, in the present review we will focus only on the cardiac effects of β-OHB.

Under pathophysiological conditions, such as acute perturbations in workload or substrate availability, the heart exhibits a metabolic flexibility, changing its fuel utilization preference from one substrate to another. Aubert et al. used a quantitative proteomics approach to screen metabolic abnormalities in mouse models with impaired fatty acid utilization. The authors discovered that the levels of the proteins involved in fatty acid oxidation were reduced. In contrast, β-OHB dehydrogenase 1 (BDH1), an essential enzyme in the ketone body oxidation pathway, was upregulated in the compensated pressure overload-induced hypertrophic hearts as well as in decompensated failing hearts (Aubert et al., 2016). The myocardium is thought to be one of the highest ketone body consumers (Cotter et al., 2013), especially when the availability of other substrates is limited. Several studies have shown that there is an increased myocardial delivery and oxidation of ketone bodies as an alternative fuel source in human patients with advanced heart failure, increasing their proportion from less than 10% to over 20% (Wende et al., 2017; Ho et al., 2019; Horton et al., 2019). This shift is thought to be an early adaptive response to maintain adequate ATP production with reduced fatty acid oxidation.

However, whether the shift is adaptive or maladaptive remains controversial. The effects of increased levels of circulating ketone bodies are also not fully understood. This review provides an overview of the role of ketone bodies in the human heart upon stress and aims to unveil the potential of altering ketone body levels as a novel therapeutic approach for treatment of cardiovascular diseases.

**β-OHB IS CARDIOPROTECTIVE IN ANIMAL MODELS**

Numerous studies have established that metabolic derangements can cause heart failure (Taegtmeyer et al., 2016; Wende et al., 2017). The myocardium of the failing heart exhibits a fetal-like metabolic profile, characterized by depressed fatty acid oxidation and increased glucose utilization (Taegtmeyer et al., 2016). Alterations in ketone body, amino acid, and protein metabolism have also been reported in the failing hearts (Wende et al., 2017). Many animal studies have focused on the cardioprotective effects of β-OHB as a stress reactive metabolite (Karwi et al., 2020).

Under normal conditions, the utilization of β-OHB in the heart is low. However, ketone body utilization becomes essential to maintain metabolic homeostasis of the heart in pathological conditions. Increased utilization of ketone bodies can improve the prognosis of heart failure patients with diabetes (Rosenstein and Hough, 2016), while failure to use ketones can worsen prognosis (Rosenstein and Hough, 2016). Succinyl-CoA:3-oxoacid-CoA transferase (SCOT) and BDH1 are two enzymes that are required for terminal oxidation of β-OHB. BDH1 is responsible for the conversion of β-OHB to acetoacetate. SCOT is responsible for converting acetoacetate to acetoacetate-CoA, which is the rate-limiting step in ketone body oxidation. Notably, the conversions are dependent on the NAD+/NADH.
ratio and succinyl-CoA and succinate levels, which are reversible in the metabolic process (Cuenoud et al., 2020) (Figure 2). In a cardiomyocyte-specific SCOT knock-out mouse model, no apparent metabolic abnormalities were observed at the baseline, although ketosis was normally induced by fasting or ketogenic diets. However, after inducing pressure overload by transverse aortic constriction (TAC), the inability of the heart to oxidize ketone bodies due to the loss of SCOT resulted in significantly increased left ventricular volume and decreased left ventricular ejection fraction. This was accompanied by an increase in the myocardial reactive oxygen species (ROS), mitochondrial damage, and disruption of myofilament ultra-structure (Schugar et al., 2014). The importance of ketone body utilization has also been demonstrated in other mouse models. After being subjected to TAC and myocardial infarction (MI) surgery, the expression of BDH1 in failing hearts was significantly upregulated, indicating increased reliance on ketone bodies as a fuel (Aubert et al., 2016). Using a cardiac-specific BDH1 overexpression mouse model, the BDH1 transgenic mice showed no differences in the baseline characteristics. However, they were resistant to pathological cardiac remodeling under the stress of TAC, with limited impairment of cardiac function and attenuated cardiac fibrosis and hypertrophy. BDH1 overexpression can also reverse ROS-induced DNA damage and protein carbonylation as well as ameliorate mitochondrial ROS generation and apoptosis in failing hearts (Uchihashi et al., 2017). These protective effects may be attributed to increased utilization of \(\beta\)-OHB in the heart.

Because ketone bodies can regulate mitochondrial metabolism and ROS production, increasing delivery of \(\beta\)-OHB to the heart undergoing stress, such as ischemia/reperfusion (I/R) and heart failure after pressure overload, may have beneficial effects. Three days of fasting can significantly increase \(\beta\)-OHB concentration and effectively protect rat hearts from acute I/R injury (Snorek et al., 2012). Fasting can limit myocardial infarct size and reduce the occurrence of premature ventricular complexes as well as reperfusion-induced ventricular arrhythmias (Snorek et al., 2012). Zou et al. showed that after long-term fasting, high concentrations of \(\beta\)-OHB can reduce myocardial infarct size and apoptosis induced by I/R injury in rat models (Zou et al., 2002). Furthermore, the delivery of exogenous \(\beta\)-OHB can protect the heart from I/R injury. Continuously delivery of \(\beta\)-OHB before reperfusion can reduce infarct size and preserve cardiac function in I/R mice (Yu et al., 2018). It can also promote autophagic flux in the myocardium, reduce mitochondrial ROS formation, increase ATP production, attenuate mitochondrial swelling, and restore mitochondrial membrane potential (Yu et al., 2018). Mice incapable of utilizing \(\beta\)-OHB display worsened cardiac remodeling, while ketogenic chow can improve left ventricle remodeling in TAC/MI mice (Yurista et al., 2021). In tachycardia-induced myopathy canine models, \(\beta\)-OHB infusion can significantly preserve systolic function and ameliorate pathologic cardiac remodeling (Horton et al., 2019). \(\beta\)-OHB is not only available in IV forms but also oral salt and ketone ester (KE) forms, making it possible to increase \(\beta\)-OHB level orally (Lopaschuk et al., 2020). In mice and rats with heart failure, KE-enriched diets improved left ventricular systolic function and cardiac remodeling in both preventive and therapeutic protocols (Yurista et al., 2021). Altogether, these results indicate that moderately elevated \(\beta\)-OHB is cardioprotective during I/R and heart failure, possibly by enhancing energetic homeostasis.
However, some controversies still exist. One study reported that prolonged exposure to β-OHB had a detrimental effect on cardiomyocytes by altering glucose uptake and increasing ROS production via inhibiting the activation of AMPK/p38 MAPK signaling pathway (Pelletier and Coderre, 2007). This was also confirmed by other studies demonstrating that a prolonged exposure to β-OHB induced by deep fasting or frequent exogenous supplementation can inhibit mitochondrial biogenesis and lead to atrial fibrosis by activating Sirtuin 7 (Sirt7) transcription through inhibiting histone deacetylases 2 (HDAC2) (Xu et al., 2021). We have summarized the discrepancies of these studies in Supplementary Table S1, which underscores the importance of the timing and concentration of β-OHB given in different heart disease models, i.e., I/R injury, pressure-overload, diabetic cardiomyopathy. Thus, further studies are needed to optimize delivery of ketone bodies as a potential therapeutic for various heart diseases.

**β-OHB IS CARDIOPROTECTIVE IN HUMANS**

Heart failure is usually accompanied by metabolic derangement. Recently, many investigations have focused on ketone body metabolism and utilization in heart failure patients (Funada et al., 2009). Patients with metabolic disorders like diabetes have a higher level of ketone bodies during diabetic ketoacidosis (Figure 1), which is thought to be deleterious. However, in both diabetic and non-diabetic patients with severe heart failure, the utilization of ketones is increased (Lommi et al., 1996) and associated with the severity and prognosis of the disease (Chung et al., 2012; Marcondes-Braga et al., 2012; Yokokawa et al., 2016). It has been shown that in patients with end-stage heart failure, β-OHB utilization is significantly increased (Horton et al., 2019). BDH1 and BDH2, which are involved in the ketone body conversion back into acetoacetate for the tricarboxylic acid cycle, are also significantly increased (Aubert et al., 2016). Furthermore, the mRNA level of the rate-limiting enzyme SCOT essential for ketone body utilization increases in failing hearts (Bedi et al., 2016). There are two heart failure types, heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). The delivery of the exogenous 3-hydroxybutyrate (3-OHB, AKA β-OHB) to patients with HFrEF has beneficial hemodynamic effects by increasing cardiac output (Nielsen et al., 2019). These beneficial effects are detectable in the physiological concentration range (0.7–1.6 mM) of circulating β-OHB levels. Intriguingly, the hemodynamic effects of β-OHB were observed in both HFrEF patients and age-matched volunteers. These results suggest that β-OHB may be used as a potential therapy for HFrEF patients (Nielsen et al., 2019).

The treatment of HFpEF is concentrated on comorbidities management (Clark et al., 2021). HFrEF and HFpEF have different metabolic patterns. HFrEF patients had a similar or lower β-OHB level than HFpEF patients (Zordoky et al., 2015; Hunter et al., 2016). Corbi et al. showed that exercise training could increase Sirt1 activity and β-OHB level with improved antioxidant capacity in HFpEF patients (Corbi et al., 2019). Whether raising β-OHB blood levels in HFpEF patients has the same hemodynamic effects as in HFrEF patients is still unknown. Further studies are needed to clarify this.

Not surprisingly, fasting-induced ketogenesis or β-OHB supplements also prevent aging-related diseases (for example, neurodegenerative diseases, cardiovascular diseases, and
cancers) and diabetes-related cardiovascular diseases. This topic was reviewed recently by Han et al. (Han et al., 2020). The mechanisms include weight loss, reduced triglycerides, LDL cholesterol, and blood glucose, and increased HDL cholesterol levels (Han et al., 2020). A randomized controlled human trial of one hundred participants carried out by Wei et al. showed that cycles of five-day fasting-mimicking diets were safe and effective in reducing markers and risk factors for aging and age-related diseases, including cardiovascular diseases (Wei et al., 2017). It was hypothesized that the reduction in serum glucose and IGF-1 contribute to the benefits. Also, the β-OHB level was significantly increased, shedding light on the β-OHB’s potential role in prevention of cardiovascular diseases (Wei et al., 2017). Although fasting-induced β-OHB is cardioprotective, a ketogenic diet with high-fat content might be detrimental in the long term. At least in rodents, a long-term ketogenic diet decreased sensitivity to peripheral insulin, impaired glucose tolerance (Kinzig et al., 2010), and induced atrial fibrosis (Xu et al., 2021). Thus, the intermittent fasting-mimicking diet cycles might be a promising lifestyle intervention to induce protective ketosis of β-OHB.

Nonetheless, increased β-OHB levels do not always correlate with positive clinical outcomes in human. Arrhythmogenic cardiomyopathy (AC) is a serious disease that may cause sudden death while lacking clinical biomarkers. A recent study demonstrated that elevated plasma β-OHB level might serve as a potential predictor of major adverse cardiovascular events (MACEs) in probands and disease progression in patients with AC and their clinically asymptomatic relatives (Song et al., 2020). It has also been reported that, as compared with normal controls, the atrial samples from patients with atrial fibrillation exhibit increased levels of ketone bodies (Xie et al., 2016).

The ability to switch to ketone bodies as energy source in stressed hearts is independent of the patient’s diabetes status (Aubert et al., 2016; Bedi et al., 2016). It is, however, still uncertain whether the enhanced cardiac ketone body utilization is the cause or the result of cardiac dysfunction. Thus, whether exogenous induction of ketosis is beneficial in all types of cardiovascular diseases requires further exploration. It is also challenging to deliver ketone bodies safely and precisely to regulate abnormal metabolism. More studies are needed to demonstrate the relationship between β-OHB and heart disease in humans and the best timing and dose of ketone body preparations to be delivered to them.

MECHANISMS UNDERLYING THE BIOLOGICAL EFFECTS OF β-OHB IN THE HEART AND OTHER ORGANS

Oxidative Roles

Ketogenesis is vital in cardiac health, especially during stresses, such as heart failure. The ketone bodies are generated in the liver, and the heart can use ketone bodies at baseline as a minor energy source and increase ketone body usage upon heart failure (Figure 2). In the failing hearts, β-OHB serves as an alternative fuel, providing more ATP than glycolysis without increasing cardiac efficiency (Lopaschuk et al., 2020). These oxidative roles of β-OHB have been reviewed recently (Lopaschuk et al., 2020). In this review, we will focus more on the non-oxidative roles of β-OHB in the heart.
Non-Oxidative Roles

Although there are many studies showing cardioprotective effects of β-OHB in addition to its oxidative roles, the underlying specific mechanisms of cardioprotection remain elusive. Elevated β-OHB has been found as an effective treatment for epilepsy (Martin et al., 2016) and played a neuro-protective role in neurodegenerative diseases, such as Parkinson’s disease (Tieu et al., 2003) and Alzheimer’s disease (Shippy et al., 2020). The possible mechanisms of β-OHB’s neuroprotective effects include mitochondrial metabolism regulation (Li et al., 2021), inhibition of the mammalian target of rapamycin (mTOR) pathway (Thau-Zuchman et al., 2021), and glutamatergic excitatory synaptic transmission reduction (Lund et al., 2009). In addition, β-OHB has also been reported to contribute to cancer cell stemness by regulating cell proliferation and facilitating key transcriptional factor expression (Wang et al., 2019; Ji et al., 2020). These functions suggest that β-OHB is not only serving as an alternative fuel but also as a signaling molecule.

β-OHB Is an Endogenous HDAC Inhibitor and Maintains Mitochondrial Homeostasis—Histone deacetylases (HDACs) play essential roles in regulating gene transcription by balancing the acetylation activities of histone acetyltransferases (HATs). Acetylation is an essential post-translational modification of many proteins, which regulates mitochondrial metabolism and function (Felisbino and Mckinsey, 2018). Acetylation of ε-lysine groups can lead to chromatin structure relaxation, thus enhancing the DNA binding proteins’ accessibility and increasing transcriptional activation (Wang et al., 2014). Since HDACs modify the lysine residue in other proteins to affect their function, HDACs are also referred to as lysine deacetylases (KDACs). According to their homology to yeast transcriptional repressors, HDACs can be divided into four classes. Class I includes HDACs 1, 2, 3, and 8; Class IIA includes HDACs 4, 5, 7, and 9; Class IIb includes HDACs 6 and 10; Class IV includes HDAC 11, which are Zn²⁺ dependent for enzymatic activity and Class III, also called Sirt1-7, uses a different NAD + dependent mechanism to regulate their activity (Gregoretti et al., 2004). The activity of HATs is dependent on nuclear acetyl-CoA concentrations (Felisbino and Mckinsey, 2018).

It has been reported that HDACs activity is elevated in models of heart failure, diabetic heart, and myocardial I/R injury (Granger et al., 2008; Nural-Guvener et al., 2014; Evans and Ferguson, 2018; Bocchi et al., 2019). Class I and II HDAC inhibitors represent a group of small molecule epigenetic modifiers that have demonstrated efficacy in animal models of heart failure over the last decade (Evans and Ferguson, 2018). HDAC inhibition has also been used as a therapeutic strategy for cardiac I/R injury (Xie et al., 2019). Emerging evidence also suggests that inhibition of HDACs protects the heart against myocardial injury and stimulates endogenous angiomyogenesis even in the diabetic heart (Bocchi et al., 2019). Thus, inhibition of HDACs using small molecules has been thought to be a promising approach to treat many pathological disorders.

Multiple pathways have been implicated in the cardioprotective effects of HDAC inhibitors, including apoptosis, inflammation, metabolism, and autophagy (Xie et al., 2014; Schotterl et al., 2015; Das Gupta et al., 2016). β-OHB is an endogenous Class I HDAC inhibitor that can cause an increase in histone acetylation (Shimazu et al., 2013). In human embryonic
kidney 293 (HEK293) cells, β-OHB can significantly increase the acetylation levels of histone H3 lysine 9 and histone H3 lysine 14. *In vitro*, β-OHB inhibits the activity of HDAC 1, 3, and 4, indicating that it is a Class I HDAC inhibitor. This inhibitory effect is through increasing histone acetylation at the FOXO3a promoter in HEK293 cells (Shimazu et al., 2013). Physiologically achievable millimolar concentrations of β-OHB can significantly increase histone acetylation through HDAC inhibition directly (Shimazu et al., 2013). However, inhibition of HDAC 6, one of the Class II HDACs, shows no benefit and is even detrimental to cardiomyocytes during I/R injury (Aune et al., 2014). Another study shows that a pretreatment with suberoylanilide hydroxamic acid (SAHA), a second-generation HDAC inhibitor, effectively protects murine fibrosarcoma L929 cells against TNF-α induced necroptosis (Wang et al., 2013). This mechanism may include induction of multiple transcription factors that can initiate cell-protective autophagy.

Since HDAC inhibitors can induce autophagy in multiple cell types, including cardiomyocytes, it will be essential to test whether β-OHB’s cardioprotective effects are mediated through autophagy. Autophagy is a lysosomal degradation pathway that plays an essential role in removing protein aggregates and damaged organelles to maintain homeostasis (Kroemer et al., 2010). In nutrient deprivation status, autophagy is thought to be an adaptive response to recycle cytosolic elements, thus providing substrates for energy metabolism (Kim et al., 2007). Autophagy has also been shown to play an essential role in mitochondrial metabolism, especially in cardiomyocytes. During reperfusion, autophagy is blocked and contributes to the reperfusion injury following ischemia (Ma et al., 2012). Dian J. Cao and his colleagues showed that autophagy is an obligatory element in cardiac hypertrophic remodeling and HDAC 1 and 2 are required effectors (Cao et al., 2011). β-OHB is a known endogenous inhibitor of HDAC 1 and 2 (Shimazu et al., 2013).

Mitophagy is a specialized autophagy mainly responsible for the clearance of damaged mitochondria by lysosomes (Whitworth and Pallanck, 2017). This is important in ischemic cardiovascular diseases because damaged mitochondria are a source of oxidative stress, which can affect mitochondrial function, thus leading to cellular degeneration in the disease status (Bingol et al., 2014). In aged rabbit hearts, β-OHB can enhance mitochondrial quality control by activating Parkin translocation while worsening mitophagy with impaired mitochondrial fission and fusion upon heart failure (Thai et al., 2019). β-OHB has also been shown to reduce oxidative stress during I/R (Shimazu et al., 2013). As a crucial part of normal and pathophysiological metabolism, β-OHB has profound effects on various mitochondrial functions, such as reducing the mitochondrial NAD couple and oxidizing coenzyme Q (Veech, 2014; Xie et al., 2016). Superoxide dismutase 2 (SOD2) is an enzyme located within the mitochondrial matrix and works as a superoxide scavenger. Under H_{2}O_{2} stimulation, β-OHB can increase FOXO3a expression level, which can induce antioxidant enzymes SOD2 and catalase, suggesting that β-OHB can reduce ROS generation in oxidative status (Nagao et al., 2016). A short-term ketogenic diet increases mitochondrial abundance in the myocardium, partially explaining the protective effect of β-OHB (Al-Zaid et al., 2007).

In diabetic patients the prevalence and severity of cardiovascular diseases are significantly increased, compared with non-diabetic patients, accompanied by a much worse prognosis.
Chen et al. showed that in diabetic hearts, HDAC inhibition plays a critical role in improving cardiac function and suppressing myocardial remodeling and is associated with decreased apoptosis, stimulation of endogenous angiogenesis, increase of anti-oxidant SOD1 and activations of GLUT1 acetylation and p38 phosphorylation (Chen et al., 2015). Since β-OHB concentrations are always kept at high levels in both type 1 and 2 diabetic patients, it is intriguing to explore the role of β-OHB in diabetic patients also suffering from a cardiovascular disease.

In summary, many cardiac stresses, such as cardiac I/R injury and diabetes, can induce HDAC activity, which contributes to the pathogenesis of heart failure. HDAC inhibition has been shown to be effective in preventing cardiac I/R injury and improve the function of a failing heart. These are probably through inducing autophagy/mitophagy. β-OHB is an endogenous HDAC inhibitor. However, whether the beneficial effects of β-OHB during cardiac I/R are exerted through regulation of the autophagy/mitophagy pathway as well as mitochondrial functions via HDAC inhibition, still needs more investigation.

β-OHB Is an Endogenous NLRP3 Inflammasome Inhibitor—The Nod-, LRR- and pyrin domain-containing protein 3 (Nlrp3) inflammasome is an important innate immune sensor acting through regulation of the caspase-1 activity and the release of proinflammatory cytokines (Lamkanfi and Dixit, 2014). Suppression of Nlrp3 inflammasome can ameliorate the progression of atherosclerosis (Duewell et al., 2010), diabetes (Ding et al., 2019), Alzheimer’s disease (Heneka et al., 2013), and other functional declines related to aging (Camell et al., 2019). Inflammation is an unmissable component of the heart stress. Numerous studies have highlighted the role of Nlrp3 inflammasome during the I/R injury event (Toldo and Abbate, 2018). β-OHB is an endogenous inhibitor of the Nlrp3 inflammasome, attenuating inflammatory responses (Yamanashi et al., 2017). In high salt-fed hypertensive rats there is a lower level of circulating β-OHB, while a nutritional supplementation of the β-OHB precursor, 1,3-butanediol, rescues kidney function, resulting in nearly normal blood pressure. The therapeutic effects of 1,3-butanediol are comparable to that of exercise. These beneficial effects are likely to be exerted through inhibition of the renal Nlrp3 inflammasome (Chakraborty et al., 2018). Another study found that the anti-inflammatory effect of ketogenic diet may be attributed to the β-OHB-mediated inhibition of Nlrp3 inflammasome formation (Youn et al., 2015). Increasing the circulating β-OHB levels by SCOT knockout in skeletal muscle reduced cardiac Nlrp3 inflammasome activation upon heart failure (Byrne et al., 2020). Endoplasmic reticulum (ER) stress can induce Nlrp3 inflammasome. Bae et al. showed that β-OHB can inhibit both ER stress and Nlrp3 inflammasome activity in rats through the AMPK activation (Bae et al., 2016). In HFpEF mice, β-OHB can delay the progression of HFpEF probably by attenuating Nlrp3 inflammasome formation and proinflammatory cytokines to prevent mitochondrial dysfunction (Deng et al., 2021).

Therefore, in addition to providing energy during heart failure and I/R, β-OHB may also reduce detrimental inflammatory responses. Thus, inhibiting Nlrp3 inflammasome formation can have positive effects, such as reduction of infarct size and prevention of heart failure. Since drugs like MCC950 are still in the development stage (van Hout et al., 2017), there is no selective Nlrp3 inflammasome inhibitors currently available for clinical use.
Alternatively, as an endogenous Nlrp3 inflammasome inhibitor, increasing the circulating β-OHB levels may be used to treat Nlrp3 inflammasome-related cardiovascular diseases, such as atherosclerosis, coronary heart diseases, and heart I/R injury (Tong et al., 2020).

**β-OHB Is an Endogenous Ligand of GPRs**—β-OHB is an endogenous ligand for a nicotinic acid receptor G protein-coupled receptor (GPR) 109A (Offermanns et al., 2011), also known as hydroxycarboxylic acid receptor 2 (HCAR2). Its specific binding can activate the adipocyte-expressed GPCRs, HM74a/PUMA-G, to reduce lipolysis in adipocytes and regulate fatty acid availability and metabolism (Tunaru et al., 2003; Taggart et al., 2005), which may have anti-atherosclerosis and anti-inflammatory effects (Lukasova et al., 2011). This suggests that activation of HCAR2 may be a potential therapeutic target for the treatment of diseases, such as atherosclerosis. β-OHB can also affect cardiovascular function via another GPCR family member, GPR41. It has been reported that β-OHB administration can decrease sympathetic outflow and heart rate through antagonizing GPR41 (Kimura et al., 2011), thereby maintaining metabolic homeostasis via the GPR41-SNS pathway (Kimura et al., 2011). The role of GPRs in ischemic neurological diseases have been well established. However, whether β-OHB can protect hearts from I/R injury via GPRs still needs to be determined. Therefore, further studies are needed to unveil the relationship between β-OHB and GPRs in cardiovascular diseases.

**Other Non-oxidative Roles of β-OHB**—In addition to acting as an HDAC inhibitor, Nlrp3 inflammasome inhibitor, and GPR ligand, ketone bodies have other roles that are likely to impact the cardiovascular system. As low as 0.5 mM β-OHB can improve cardiac cell excitation-contraction coupling under hypoxia, providing evidence that β-OHB can exert cardioprotective benefits under stress (Klos et al., 2019). β-OHB can also reduce oxidative stress and induce anti-aging effects through binding to hnRNP A1 to upregulate Oct4 expression at the concentration of 4 mM in the vascular system (Han et al., 2018). Besides enhancing gene expression by inhibiting HDACs, β-OHB can also promote protein hyperacetylation via increasing cellular acetyl-CoA levels to maintain metabolic balance (Newman and Verdin, 2014). Lysine β-hydroxybutyrylation (Kbhb) is a post-translational modification of histone induced by increased β-OHB levels, which can activate gene transcription and cell proliferation (Xie et al., 2016). It has been reported that Kbhb is involved in the upregulation of genes in the starvation-responsive metabolic pathways (Xie et al., 2016) and β-OHB may become a new target for cancer treatment through regulating p53 activity (Liu et al., 2019). These observations suggest that β-OHB’s cardiac protective effects may be achieved through other epigenetic mechanisms other than HDAC inhibition. Poly-R-β-hydroxybutyrate (PHB) is a polymer of β-OHB and a part of the mitochondrial membrane system (Dedkova and Blatter, 2014). It can increase mitochondrial membrane permeability by regulating the opening of the permeability transition pores required for cardiovascular metabolism and apoptosis pathways (Dedkova, 2016). These studies demonstrate that β-OHB plays an essential role in multiple pathways in non-cardiomyocytes, warranting more studies to elucidate its function in cardiovascular diseases.
SGLT2 INHIBITORS CAN INCREASE THE PRODUCTION OF β-OHB

The sodium-glucose cotransporter-2 inhibitors (SGLT2i) are diabetic medications to control blood glucose. SGLT2i targets renal glucose reabsorption in an insulin-independent manner, which can induce glycosuria of 60–90 g/day (Tahrani et al., 2013). Unlike the traditional antidiabetic agents, SGLT2i offers unique benefits to type 2 diabetic patients with high cardiovascular risks. Many clinical studies have been carried out to show remarkable cardiovascular outcomes in patients using SGLT2i (Zinman et al., 2015; Neal et al., 2017; Wiviott et al., 2019).

The SGLT family is composed of seven isoforms: SGLT1-6 and Sodium-myo-inositol co-transporter 1 (SMIT1). SGLT1 has the highest affinity for glucose in the gastrointestinal tract and is also involved in kidney and cardiac glucose handling (Wright et al., 2011). In human heart, GLUT4 is the major isoform that represents approximately 70% of the total glucose transporters. Expression of SGLT1 is increased in patients with end-stage cardiomyopathy secondary to type 2 diabetes. Increased expression of SGLT1 is a compensatory mechanism to the reduction in cardiac GLUT1 and GLUT4 expression (Szablewski, 2017). Although SGLT1 is thought to be an important cardiac glucose transporter in type 2 diabetic patients (Szablewski, 2017), a recent study demonstrated that phlorizin, a dual SGLT1/2 inhibitor, can reduce cardiomyocyte glucose uptake independent of SGLT1, suggesting that SGLT1/2 inhibitor might inhibit other glucose transporters (Ferte et al., 2021). In diabetic mice, inhibition of SGLT1 using shRNA, could alleviate inflammation and pyroptosis induced by hyperglycemia (Sun et al., 2021). To investigate whether using a dual SGLT1/2 inhibitor can enhance the protective effects of SGLT2i, Bode et al. carried out a study in mouse HFpEF models and found that the SGLT1/2 inhibitor sotagliflozin can improve atrial remodeling and exhibit anti-arrhythmic effects (Bode et al., 2021). A recent study showed that the dual SGLT1/2 inhibitors may protect patients with diabetes from MI and stroke better, while the beneficial effects in patients without diabetes require more evaluation (Pitt and Bhatt, 2021). SGLT2 is the main co-transporter in humans that helps reabsorbing 80–90% of the glucose filtered by the glomerulus (Bonora et al., 2020), and SGLT1 helps reabsorbing additional renal glucose that evades SGLT2 (Bertrand et al., 2020). However, since the SGLT2i are available as therapeutic agents, most of the current clinical results reviewed are from SGLT2i.

In a clinical trial involving 7,020 patients, compared with placebo, empagliflozin showed a lower rate of primary composite cardiovascular outcome and all-cause mortality in patients with type 2 diabetes (Zinman et al., 2015). Neal et al. showed similar results that canagliflozin can lower the risk of cardiovascular events with a greater risk of amputation at the level of the toe or metatarsal (Neal et al., 2017). Wiviott et al. showed that treatment with dapagliflozin resulted in a lower rate of cardiovascular death or hospitalization for heart failure in patients with type 2 diabetes (Wiviott et al., 2019). Recent data from DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), EMPEROR-Reduced (EMPagliflozin outcomeRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction) and EMPA-TROPISM (Are the “Cardiac Benefits” of Empagliflozin Independent of Its Hypoglycemic Activity) showed the benefit of SGLT2i in both diabetic and non-diabetic heart failure patients (Mcmurray et al., 2019; Packer et al., 2020; Santos-
Gallego et al., 2021). Dapagliflozin can reduce the risk of cardiovascular death or heart failure exacerbation in HFrEF patients shown in the DAPA-HF trial (Mcmurray et al., 2019). Empagliflozin significantly improves cardiovascular and renal outcomes in patients independent of baseline diabetes status in the EMOEROR-Reduced trial (Packer et al., 2020) and significantly improves cardiac function and quality of life in HFrEF patients in the EMPA-TROPISM trial (Santos-Gallego et al., 2021). The clinical trial to investigate the effects of SGLT2i on HFpEF is still in progress (Anker et al., 2020).

Although the beneficial effects of SGLT2i in heart failure can be attributed to improved volume status, glucose-lowering, etc., the exact mechanisms of achieving the cardiac benefits of SGLT2i are not fully delineated (Santos-Gallego et al., 2021). SGLT2i can induce a persistently low level of ketone body production, mainly β-OHB. Mechanistically, SGLT2i decreases the level of glucose in the blood and increases the production of glucagon, which promotes ketogenesis. On the other hand, SGLT2 receptors present on the surface of pancreatic α-cells can act as glucose sensors (Bonner et al., 2015). Furthermore, SGLT2i can increase lipolysis and the subsequent production of ketone bodies in the liver (Taylor et al., 2015). Ketone bodies use less oxygen to generate the same amount of ATP as glucose and fatty acids (Puchalska and Crawford, 2017). Thus, the diabetic hearts can benefit from the SGLT2i treatment. Mildly elevated ketone levels can promote fuel efficiency and reduce ROS formation, which might improve cardiac function and the prognosis of heart failure (Oh et al., 2019). In addition to inducing ketosis, SGLT2i can mediate other effects, like the natriuretic effect, plasma volume contraction, to reduce cardiac preload. Also, through lowering blood pressure and arterial stiffness, cardiac afterload can be reduced (Selvaraj et al., 2020). In addition, SGLT2i can attenuate Nlrp3 inflammasome activation in isolated macrophages, which has also been proved in diabetic patients with cardiovascular diseases (Kim et al., 2020). Since SGLT2i’s targets are mainly located on the renal proximal tubular epithelium, SGLT2i mediated natriuresis may account for its hemodynamic improvement effect (Sano, 2017). To what degree SGLT2i’s cardiac protection is mediated by β-OHB remains challenging to clarify. Verma et al. showed that empagliflozin, or β-OHB, can enhance cardiac metabolism in diabetic mice by increasing ATP production rates without affecting cardiac efficiency (Verma et al., 2018). In a study using a novel ketone probe and magnetic resonance spectroscopy, empagliflozin was shown to be able to increase circulating β-OHB levels but not myocardial ketone body utilization in spontaneously hypertensive heart failure (Abdurrahchim et al., 2019a). This suggests that SGLT2i may be beneficial to the heart, mainly via β-OHB through its non-oxidative functions. Furthermore, SGLT2i can improve glycemic regulation via an insulin-independent mechanism (Ferrannini and Solini, 2012). The therapeutic application of SGLT2i could lead to weight loss (Merovci et al., 2014), correction of hyperinsulinemia (Matsubayashi et al., 2020), and reduced hyperleptinemia (Vickers et al., 2014). SGLT2i could also modulate inflammation via IL-1β (Nakatsu et al., 2017) and Nlrp3 inflammasome (Sukhanov et al., 2021). These features together contribute to SGLT2i’s therapeutic effects in patients with heart failure.

Among multiple classes of antidiabetic agents, SGLT2i showed significant cardiovascular benefits, which might be attributed, at least partially, to its ability to increase the concentration of ketone bodies, especially β-OHB. SGLT2i is beyond its initial objective as an antidiabetic drug and the ongoing studies could further uncover the underlying molecular
mechanisms. With a better understanding of the mechanism, we are on track to develop novel heart failure treatments in patients with or without diabetes.

**POTENTIAL THERAPEUTIC APPLICATIONS OF β-OHB**

Given the benefits of exogenous β-OHB in patients with heart failure, several therapeutics have been developed to deliver β-OHB. β-OHB infusion in patients with HFrEF can significantly improve cardiac output and reduce systemic vascular resistance in a dose-dependent manner without impairing the myocardial external energy efficiency (Nielsen et al., 2019). Oral forms of β-OHB include 1,3-butaneediol (Scott et al., 2019), medium-chain triglyceride (MCT) supplementation (Brunner et al., 2021), KEs, and ketone salts (Stubbs et al., 2017). Among them, KEs are the most promising therapeutics, with smaller effective doses and fewer side effects. KEs are typically comprised of several ketones or ketogenic precursors, and their decomposition products can be directly absorbed into blood as ketone bodies or their precursors (Clarke et al., 2012). Several clinical trials have been carried out to test KEs’ effects in healthy and cardiovascular disease conditions. KEs can reduce blood glucose, free fatty acids, and triglyceride levels (Stubbs et al., 2017), as well as lower plasma insulin, ghrelin, glucagon-like peptide-1, and peptide tyrosine levels in healthy adults (Stubbs et al., 2018). More ongoing studies are testing the effect of KEs in pre-diabetic patients. These studies will determine whether regulating ketone levels can become a promising therapeutic strategy in diseases with metabolic disorders like diabetes and heart failure.

**CONCLUSION AND PERSPECTIVES**

Despite the advances in the prevention, diagnosis, and treatment of cardiovascular diseases, they remain to be the leading cause of hospitalization and mortality. Close attention has been paid to the myocardial metabolism and increased utilization of β-OHB during cardiac stresses, such as heart failure and I/R injury. Besides its role as an energy source, β-OHB may have beneficial effects on the myocardium by inhibiting HDAC activity and Nlrp3 inflammasome formation and may play a vital role in the SGLT2i’s cardioprotection effects (Figure 3). Although most of the studies showed beneficial effects of mildly to moderately increased β-OHB in heart failure and I/R injury, there is some evidence that a prolonged exposure to or high blood levels of β-OHB are detrimental to the hearts. It is also noteworthy that the effects of β-OHB may depend on the formulation, dose, and delivery timing. Cardiac function is regulated by many signaling pathways affected by β-OHB, which makes it challenging to study. However, our efforts to further elucidate the mechanisms underlying the role of β-OHB during cardiac stresses may uncover a new era of heart failure and cardiac I/R injury management with more efficacious and safer therapeutics.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.
FUNDING

This work was supported by grants from NIH: HL141620 (MX) and HL153501 (MX).

REFERENCES

Abdurrachim D, Teo XQ, Woo CC, Chan WX, Lalic J, Lam CSP, et al. (2019a). Empagliflozin Reduces Myocardial Ketone Utilization while Preserving Glucose Utilization in Diabetic Hypertensive Heart Disease: A Hyperpolarized 13 C Magnetic Resonance Spectroscopy Study. Diabetes Obes. Metab 21, 357–365. doi:10.1111/dom.13556 [PubMed: 30225964]

Abdurrachim D, Woo CC, Teo XQ, Chan WX, Radka GK, and Lee PTH (2019b). A New Hyperpolarized (13)C Ketone Body Probe Reveals an Increase in Acetoacetate Utilization in the Diabetic Rat Heart. Sci. Rep 9, 5553. doi:10.1038/s41598-019-39378-w [PubMed: 30940842]

Al-Zaid NS, Dashi HM, Mathew TC, and Juggi JS (2007). Low Carbohydrate Ketogenic Diet Enhances Cardiac Tolerance to Global Ischaemia. Acta Cardiol. 62, 381–389. doi:10.2143/AC.62.4.2022282 [PubMed: 17824299]

Anker SD, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, Bocchi E, et al. (2020). Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial. Eur. J. Heart Fail 22, 2383–2392. doi:10.1002/ejhf.2064 [PubMed: 33251670]

Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, et al. (2016). The Failing Heart Relies on Ketone Bodies as a Fuel. Circulation 133, 698–705. doi:10.1161/circulationaha.115.017355 [PubMed: 26819376]

Aune SE, Herr DJ, Mani SK, and Menick DR (2014). Selective Inhibition of Class I but Not Class IIb Histone Deacetylases Exerts Cardiac protection from Ischemia Reperfusion. J. Mol. Cell Cardiol 72, 138–145. doi:10.1016/j.yjmcc.2014.03.005 [PubMed: 24632412]

Bae HR, Kim DH, Park MH, Lee B, Kim MJ, Lee EK, et al. (2016). β-Hydroxybutyrate Suppresses Inflammation by Ameliorating Endoplasmic Reticulum Stress via AMPK Activation. Oncotarget 7, 66444–66454. doi:10.18632/oncotarget.12119 [PubMed: 27661104]

Bedi KC Jr., Snyder NW, Brandimarto J, Aziz M, Mesaros C, Worth AJ, et al. (2016). Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation 133, 706–716. doi:10.1161/circulationaha.115.017545 [PubMed: 26819374]

Bertrand L, Auguier J, Renguet E, Angé M, Cumps J, Hormann S, et al. (2020). Glucose Transporters in Cardiovascular System in Health and Disease. Pflugers Arch. 472, 1385–1399. doi:10.1007/s00424-020-02444-8 [PubMed: 32809061]

Bingol B, Tea JS, Phu L, Reichelt M, Bakalarski CE, Song Q, et al. (2014). The Mitochondrial Deubiquitinase USP30 Opposes Parkin-Mediated Mitophagy. Nature 510, 370–375. doi:10.1038/nature13418 [PubMed: 24896179]

Bocchi L, Motta BM, Savi M, Vilella R, Meraviglia V, Rizzi F, et al. (2019). The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Restores Cardiomyocyte Contractility in a Rat Model of Early Diabetes. J. Mol. Sci 20, 1873. doi:10.3390/jms20081873

Bode D, Semmler L, Waku P, Hegemann N, Primessnig U, Beindorff N, et al. (2021). Dual SGLT-1 and SGLT-2 Inhibition Improves Left Atrial Dysfunction in HFpEF. Cardiovasc. Diabetol 20, 7. doi:10.1186/s12933-020-01208-z [PubMed: 33413413]

Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, et al. (2015). Inhibition of the Glucose Transporter SGLT2 with Dapagliflozin in Pancreatic Alpha Cells Triggers Glucagon Secretion. Nat. Med 21, 512–517. doi:10.1038/nm.3828 [PubMed: 25894829]

Bonora BM, Avogaro A, and Fadini GP (2020). Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence. Diabetes. Metab. Syndr. Obes Vol. 13, 161–174. doi:10.2147/dmso.s233538 [PubMed: 32021362]

Brunner B, Rauch E, Ari C, D’agostino DP, and Kovacs Z (2021). Enhancement of Ketone Supplements-Evoked Effect on Absence Epileptic Activity by Co-administration of Uridine in Wistar Albino Glaxo Rijswijk Rats. Nutrients 13, 234. doi:10.3390/nu13010234 [PubMed: 33467454]
Byrne NJ, Soni S, Takahara S, Ferdaoussi M, Al Batran R, Darwesh AM, et al. (2020). Chronically Elevating Circulating Ketones Can Reduce Cardiac Inflammation and Blunt the Development of Heart Failure. Circ. Heart Fail 13, e006573. doi:10.1161/circheartfailure.119.006573 [PubMed: 32493060]

Cahill GF Jr. (2006). Fuel Metabolism in Starvation. Annu. Rev. Nutr 26, 1–22. doi:10.1146/annurev.nutr.26.061505.111258 [PubMed: 16846989]

Camell CD, Günther P, Lee A, Goldberg EL, Spadaro O, Youm Y-H, et al. (2019). Aging Induces an Nlrp3 Inflammasome-dependent Expansion of Adipose B Cells that Impairs Metabolic Homeostasis. Cel Metab. 30, 1024–1039. doi:10.1016/j.cmet.2019.10.006

Cao DJ, Wang ZV, Battiprolu PK, Jiang N, Morales CR, Kong Y, et al. (2011). Histone Deacetylase (HDAC) Inhibitors Attenuate Cardiac Hypertrophy by Suppressing Autophagy. Proc. Natl. Acad. Sci 108, 4123–4128. doi:10.1073/pnas.1015081108 [PubMed: 21367993]

Chakraborty S, Galla S, Cheng X, Yeo J-Y, Mell B, Singh V, et al. (2018). Salt-Responsive Metabolite, β-Hydroxybutyrate, Attenuates Hypertension. Cel. Rep 25, 677–689. doi:10.1016/j.celrep.2018.09.058

Chen W, Sharma G, Jiang W, Maptue NR, Malloy CR, Sherry AD, et al. (2019). Metabolism of Hyperpolarized (13) C-Acetoacetate to Beta-Hydroxybutyrate Detects Real-Time Mitochondrial Redox State and Dysfunction in Heart Tissue. NMR. Biomed 32, e4091. doi:10.1002/nbm.4091 [PubMed: 30968985]

Chen Y, Du J, Zhao YT, Zhang L, Lv G, Zhuang S, et al. (2015). Histone Deacetylase (HDAC) Inhibition Improves Myocardial Function and Prevents Cardiac Remodeling in Diabetic Mice. Cardiovasc. Diabetol 14, 99. doi:10.1186/s12933-015-0262-8 [PubMed: 26245924]

Chung JH, Kim J-S, Kim OY, Kang S-M, Hwang G-S, and Shin M-J (2012). Urinary Ketone Is Associated with the Heart Failure Severity. Clin. Biochem 45, 1697–1699. doi:10.1016/j.cl servicebiochem.2012.08.013 [PubMed: 22935565]

Clark H, Rana R, Gow J, Pearson M, Van Der Touw T, and Smart N (2021). Hospitalisation Costs Associated with Heart Failure with Preserved Ejection Fraction (HfEF): a Systematic Review. Heart Fail. Rev [Epub ahead of print]. doi:10.1007/s10741-021-10097-7

Clarke K, Tchabanenko K, Pawlosky R, Carter E, Knight NS, Murray AJ, et al. (2012). Oral 28-day and Developmental Toxicity Studies of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate. Regul. Toxicol. Pharmacol 63, 196–208. doi:10.1016/j.yrtph.2012.04.001 [PubMed: 22504461]

Corbi G, Conti V, Troisi J, Colucci A, Manzo V, Di Pietro P, et al. (2019). Cardiac Rehabilitation Increases SIRT1 Activity and Beta-Hydroxybutyrate Levels and Decreases Oxidative Stress in Patients with HF with Preserved Ejection Fraction. Oxid Med. Cel Longev 2019, 7049237. doi:10.1155/2019/7049237

Deng Y, Xie M, Li Q, Xu X, Ou W, Zhang Y, et al. (2021). Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HfEF. Circ. Res 128, 232–245. doi:10.1161/circresaha.120.317933 [PubMed: 33176578]

Dedkova EN, and Blatter LA (2014). Role of Beta-Hydroxybutyrate, its Polymer Poly-Beta-Hydroxybutyrate and Inorganic Polyphosphate in Mammalian Health and Disease. Front. Physiol 5, 260. doi:10.3389/fphys.2014.00260 [PubMed: 25101001]

Dedkova EN (2016). Inorganic Polyphosphate in Cardiac Myocytes: from Bioenergetics to the Permeability Transition Pore and Cell Survival. Biochem. Soc. Trans. 44, 25–34. doi:10.1042/bst20150218 [PubMed: 26862184]

Deng Y, Xie M, Li Q, Xu X, Ou W, Zhang Y, et al. (2021). Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HfEF. Circ. Res 128, 232–245. doi:10.1161/circresaha.120.317933 [PubMed: 33176578]
Ding S, Xu S, Ma Y, Liu G, Jang H, and Fang J (2019). Modulatory Mechanisms of the NLRP3 Inflammasomes in Diabetes. Biomolecules 9. 850. doi:10.3390/biom9120850
Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimir G, Bauernfeind FG, et al. (2010). NLRP3 Inflammasomes Are Required for Atherogenesis and Activated by Cholesterol Crystals. Nature 464, 1357–1361. doi:10.1038/nature08938 [PubMed: 20428172]
Evans LW, and Ferguson BS (2018). Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure. Nutrients 10. 1120. doi:10.3390/nu10081120
Felisbino MB, and Mckinsey TA (2018). Epigenetics in Cardiac Fibrosis. JACC: Basic Translational Sci. 3, 704–715. doi:10.1016/j.jacbts.2018.05.003
Ferrannini E, and Solini A (2012). SGLT2 Inhibition in Diabetes Mellitus: Rationale and Clinical Prospects. Nat. Rev. Endocrinol 8, 495–502. doi:10.1038/nrendo.2011.243 [PubMed: 22310849]
Ferté L, Marino A, Battault S, Bultot L, Van Steenbergen A, Bol A, et al. (2021). New Insight in Understanding the Contribution of SGLT1 in Cardiac Glucose Uptake: Evidence for a Truncated Form in Mice and Humans. Am. J. Physiology-Heart Circulatory Physiol 320, H838–H853. doi:10.1152/ajpheart.00736.2019
Funada J, Betts TR, Hodson L, Humphreys SM, Timperley J, Frayn KN, et al. (2009). Substrate Utilization by the Failing Human Heart by Direct Quantification Using Arterio-Venous Blood Sampling. PLoS One 4, e7533. doi:10.1371/journal.pone.0007533 [PubMed: 19844574]
Gibb AA, and Hill BG (2018). Metabolic Coordination of Physiological and Pathological Cardiac Remodeling, Circ. Res 123, 107–128. doi:10.1161/circresaha.118.312017 [PubMed: 29929976]
Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T, et al. (2008). Histone Deacetylase Inhibition Reduces Myocardial Ischemia-reperfusion Injury in Mice. FASEB. J 22, 3549–3560. doi:10.1096/fj.08-108548 [PubMed: 18606865]
Gregoretti I, Lee Y-M, and Goodson HV (2004). Molecular Evolution of the Histone Deacetylase Family: Functional Implications of Phylogenetic Analysis. J. Mol. Biol 338, 17–31. doi:10.1016/j.jmb.2004.02.006 [PubMed: 15050820]
Han Y.-m., Bedarida T, Ding Y, Somba BK, Lu Q, Wang Q, et al. (2018). β-Hydroxybutyrate Prevents Vascular Senescence through hnRNP A1-Mediated Upregulation of Oct4. Mol. Cell 71, 1064–1078. doi:10.1016/j.molcel.2018.07.036
Han Y-M, Ramprasath T, and Zou M-H (2020). β-Hydroxybutyrate and its Metabolic Effects on Age-Associated Pathology. Exp. Mol. Med 52, 548–555. doi:10.1038/s12276-020-0415-z [PubMed: 32269287]
Henneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. (2013). NLRP3 Is Activated in Alzheimer’s Disease and Contributes to Pathology in APP/PS1 Mice. Nature 493, 674–678. doi:10.1038/nature11729 [PubMed: 23254930]
Ho KL, Zhang L, Wagg C, Al Batran R, Gopal K, Levasseur J, et al. (2019). Increased Ketone Body Oxidation Provides Additional Energy for the Failing Heart without Improving Cardiac Efficiency. Cardiovasc. Res 115, 1606–1616. doi:10.1093/cvr/cvz045 [PubMed: 30778524]
Horton JL, Davidson MT, Kurishima C, Vega RB, Powers JC, Matsuura TR, et al. (2019). The Failing Heart Utilizes 3-hydroxybutyrate as a Metabolic Stress Defense. JCI. Insight 4. e124079. doi:10.1172/jci.insight.124079
Hunter WG, Kelly JP, Mgarrah RW 3rd, Khouri MG, Craig D, Haynes C, et al. (2016). Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure with Preserved versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. J. Am. Heart Assoc 5, e003190. doi:10.1161/jaha.115.003190 [PubMed: 27473038]
Ji CC, Hu YY, Cheng G, Liang L, Gao B, Ren YP, et al. (2020). A Ketogenic Diet Attenuates Proliferation and Stemness of Glioma Stem like Cells by Altering Metabolism Resulting in Increased ROS Production. Int. J. Oncol 56, 606–617. doi:10.3892/ijo.2019.4942 [PubMed: 31894296]
Karwi QG, Biswas D, Pulinilkunnil T, and Lopaschuk GD (2020). Myocardial Ketones Metabolism in Heart Failure. J. Card. Fail 26, 998–1005. doi:10.1016/j.cardfail.2020.04.005 [PubMed: 32442517]
Kim I, Rodriguez-Enriquez S, and Lemasters JJ (2007). Selective Degradation of Mitochondria by Mitophagy. Arch. Biochem. Biophys 462, 245–253. doi:10.1016/j.abb.2007.03.034 [PubMed: 17475204]

Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, et al. (2020). SGLT2 Inhibition Modulates NLRP3 Inflammasome Activity via Ketones and Insulin in Diabetes with Cardiovascular Disease. Nat. Commun 11, 2127. doi:10.1038/s41467-020-15983-6 [PubMed: 32358544]

Kimura I, Inoue D, Maeda T, Har a T, Ichimura A, Miyauchi S, et al. (2011). Short-chain Fatty Acids and Ketones Directly Regulate Sympathetic Nervous System via G Protein-Coupled Receptor 41 (GPR41). Proc. Natl. Acad. Sci 108, 8030–8035. doi:10.1073/pnas.1016088108 [PubMed: 21518883]

Kinzig KP, Honors MA, and Hargrave SL (2010). Insulin Sensitivity and Glucose Tolerance Are Altered by Maintenance on a Ketogenic Diet. Endocrinology 151, 3105–3114. doi:10.1210/en.2010-0175 [PubMed: 20427477]

Klos M, Morgenstern S, Hicks K, Suresh S, and Devaney EJ (2019). The Effects of the Ketone Body β-hydroxybutyrate on Isolated Rat Ventricular Myocyte Excitation-Contraction Coupling. Arch. Biochem. Biophys 662, 143–150. doi:10.1016/j.abb.2018.11.027 [PubMed: 30543786]

Kroemer G, Mariño G, and Levine B (2010). Autophagy and the Integrated Stress Response. Mol. Cell 40, 280–293. doi:10.1016/j.molcel.2010.09.023

Laffel L (1999). Ketone Bodies: a Review of Physiology, Pathophysiology and Application of Monitoring to Diabetes. Diabetes Metab. Res. Rev 15, 412–426. doi:10.1002/(sici)1520-7560(199911/12)15:6<412::aid-dmrr72>3.0.co;2-8 [PubMed: 10634967]

Lamkanfi M, and Dixit VM (2014). Mechanisms and Functions of Inflammasomes. Cell 157, 1013–1022. doi:10.1016/j.cell.2014.04.007 [PubMed: 24855941]

Li Y, Zhang X, Ma A, and Kang Y (2021). Rational Application of Beta-Hydroxybutyrate Attenuates Ischemic Stroke by Suppressing Oxidative Stress and Mitochondrial-dependent Apoptosis via Activation of the Erk/CREB/enOS Pathway. ACS Chem. Neurosci 12, 1219–1227. doi:10.1021/acschemneuro.1c00046 [PubMed: 33739811]

Liu K, Li F, Sun Q, Lin N, Han H, You K, et al. (2019). p53 Beta-Hydroxybutyrylation Attenuates P53 Activity. Cell Death Dis. 10, 243. doi:10.1038/s41419-019-1463-y [PubMed: 30858356]

Lommi J, Kupari M, Koskinnen P, Näveri H, Leinonen H, Pulkkki K, et al. (1996). Blood Ketone Bodies in Congestive Heart Failure. J. Am. Coll. Cardiol 28, 665–672. doi:10.1016/0735-1097(96)00214-8 [PubMed: 8772754]

Lopaschuk GD, Karwi QG, Ho KL, Pherwani S, and Ketema EB (2020). Ketone Metabolism in the Failing Heart. Biochim. Biophys. Acta (Bba) - Mol. Cel Biol. Lipids 1865, 158813. doi:10.1016/j.bbalip.2020.158813

Lukasova M, Malaval C, Gille A, Kero J, and Offermanns S (2011). Nicotinic Acid Inhibits Progression of Atherosclerosis in Mice through its Receptor GPR109A Expressed by Immune Cells. J. Clin. Invest 121, 1163–1173. doi:10.1172/jci41651 [PubMed: 21317532]

Lund TM, Risa Ø, Sonnewald U, Schousboe A, and Waagepetersen HS (2009). Availability of Neurotransmitter Glutamate Is Diminished when β-hydroxybutyrate Replaces Glucose in Cultured Neurons. J. Neurochem 110, 80–91. doi:10.1111/j.1471-4159.2009.06115.x [PubMed: 19457063]

Ma X, Liu F, Hoyl SR, Godar RJ, Weinheimer CJ, and Diwan A (2012). Autophagy Is Impaired in Cardiac Ischemia-Reperfusion Injury. Autophagy 8, 1394–1396. doi:10.4161/auto.21036 [PubMed: 22889942]

Marcondes-Braga FG, Gutz IGR, Batista GL, Saldiva PHN, Ayub-Ferreira SM, Issa VS, et al. (2012). Exhaled Acetone as a New Biomarker of Heart Failure Severity. Chest 142, 457–466. doi:10.1378/chest.11-2892 [PubMed: 22345322]

Martin K, Jackson CF, Levy RG, and Cooper PN (2016). Ketogenic Diet and Other Dietary Treatments for Epilepsy. Cochrane Database Syst. Rev 2, CD001903. doi:10.1002/14651858.CD001903.pub3 [PubMed: 26859528]

Matsubayashi Y, Yoshida A, Suganami H, Osawa T, Furukawa K, Suzuki H, et al. (2020). Association of Increased Hepatic Insulin Clearance and Change in Serum Triglycerides or β-hydroxybutyrate Concentration via the Sodium/glucose-cotransporter 2 Inhibitor Tofogliflozin. Diabetes Obes. Metab 22, 947–956. doi:10.1111/dom.13980 [PubMed: 31984623]
Mcmurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N. Engl. J. Med 381, 1995–2008. doi:10.1056/nejmoa1911303 [PubMed: 31535829]

Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. (2014). Dapagliflozin Improves Muscle Insulin Sensitivity but Enhances Endogenous Glucose Production. J. Clin. Invest 124, 509–514. doi:10.1172/jci70704 [PubMed: 24463448]

Nagao M, Toh R, Irimo Y, Mori T, Nakajima H, Hara T, et al. (2016). β-Hydroxybutyrate Elevation as a Compensatory Response against Oxidative Stress in Cardiomyocytes. Biochem. Biophysical Res. Commun 475, 322–328. doi:10.1016/j.brc.2016.05.097

Nakatsu Y, Kokubo H, Bumdelger B, Yoshizumi M, Yamamotoya T, Matsumana Y, et al. (2017). The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice. Int. J. Mol. Sci 18, 1704. doi:10.3390/ijms18081704

Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. (2017). Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N. Engl. J. Med 377, 644–657. doi:10.1056/nejmoa1611925 [PubMed: 28605608]

Newman JC, and Verdin E (2014). Ketone Bodies as Signaling Metabolites. Trends Endocrinol. Metab 25, 42–52. doi:10.1016/j.tem.2013.09.002 [PubMed: 24140022]

Nielsen R, Møller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, et al. (2019). Cardiovascular Effects of Treatment with the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation 139, 2129–2141. doi:10.1161/circulationaha.118.036459 [PubMed: 30884964]

Nural-Guvener HF, Zakharova L, Nimlos J, Popovic S, Mastroeni D, and Gaballa MA (2014). HDAC Class I Inhibitor, Mocetinostat, Reverses Cardiac Fibrosis in Heart Failure and Diminishes CD90+ Cardiac Myofibroblast Activation. Fibrogenesis. Tissue. Repair 7, 10. doi:10.1186/1755-1536-7-10 [PubMed: 25024745]

Offermanns S, Colletti SL, Loenenberg TW, Semple G, Wise A, and IJzerman AP (2011). International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-Carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B). Pharmacol. Rev 63, 269–290. doi:10.1124/pr.100.003301 [PubMed: 21454438]

Oh C-M, Cho S, Jang J-Y, Kim H, Chun S, Choi M, et al. (2019). Cardioprotective Potential of an SGLT2 Inhibitor against Doxorubicin-Induced Heart Failure. Korean Circ. J 49, 1183–1195. doi:10.4070/kcj.2019.0180 [PubMed: 31456369]

Packer M, Anker SD, Butler J, Filipatos G, Pocock SJ, Carson P, et al. (2020). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N. Engl. J. Med 383, 1413–1424. doi:10.1056/nejmoa2022190 [PubMed: 32865377]

Pelletier A, and Coderre L (2007). Ketone Bodies Alter Dinitrophenol-Induced Glucose Uptake through AMPK Inhibition and Oxidative Stress Generation in Adult Cardiomyocytes. Am. J. Physiology-Endocrinology Metab 292, E1325–E1332. doi:10.1152/ajpendo.00186.2006

Pitt B, and Bhatt DL (2021). Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes Mellitus? Circulation. [Epub ahead of print]. doi:10.1161/circulationaha.121.054442

Puchalska P, and Crawford PA (2017). Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. Cel. Metab 25, 262–284. doi:10.1016/j.cmet.2016.12.022

Rosenstein R, and Hough A (2016). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med 374, 1093–1094. doi:10.1056/NEJMoa1600827

Sano M (2017). Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. J. Clin. Med. Res 9, 457–460. doi:10.14740/jocmr3011w [PubMed: 28496544]

Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, et al. (2021). Randomized Trial of Empagliflozin in Nondiabetic Patients with Heart Failure and Reduced Ejection Fraction. J. Am. Coll. Cardiol 77, 243–255. doi:10.1016/j.jacc.2020.11.008 [PubMed: 33197559]

Schotterl S, Brennenstuhl H, and Naumann U (2015). Modulation of Immune Responses by Histone Deacetylase Inhibitors. Crit. Rev. Oncog 20, 139–154. doi:10.1615/critrevoncog.2014012393 [PubMed: 25746108]
Schugar RC, Moll AR, André d’Avignon D, Weinheimer CJ, Kovacs A, and Crawford PA (2014). Cardiomyocyte-specific Deficiency of Ketone Body Metabolism Promotes Accelerated Pathological Remodeling. Mol. Metab 3, 754–769. doi:10.1016/j.molmet.2014.07.010 [PubMed: 25353003]

Scott BE, Laursen PB, James LJ, Boxer B, Chandler Z, Lam E, et al. (2019). The Effect of 1,3-butanediol and Carbohydrate Supplementation on Running Performance. J. Sci. Med. Sport 22, 702–706. doi:10.1016/j.jsams.2018.11.027 [PubMed: 30553764]

Selvaraj S, Kelly DP, and Margulies KB (2020). Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure. Circulation 141, 1800–1812. doi:10.1161/ circulationaha.119.045033 [PubMed: 32479196]

Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, et al. (2013). Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor. Science 339, 211–214. doi:10.1126/science.1227166 [PubMed: 23223453]

Shippy DC, Wilhelm C, Viharkumar PA, Raife TJ, and Ulland TK (2020). Beta-Hydroxybutyrate Inhibits Inflammation by Attenuating Alzheimer’s Disease Pathology. J. Neuroinflammation 17, 280. doi:10.1186/s12974-020-01948-5 [PubMed: 32958021]

Snorek M, Hodyc D, Sedivý V, Durisová J, Skoumalová A, Wilhelm J, et al. (2012). Short-term Fasting Reduces the Extent of Myocardial Infarction and Incidence of Reperfusion Arrhythmias in Rats. Physiol. Res 61, 567–574. doi:10.33549/physiolres.92338 [PubMed: 23098657]

Song JP, Chen L, Chen X, Ren J, Zhang NN, Tirasawasdichai T, et al. (2020). Elevated Plasma Beta-Hydroxybutyrate Predicts Adverse Outcomes and Disease Progression in Patients with Arrhythmogenic Cardiomyopathy. Sci. Transl Med 12. eaay8329. doi:10.1126/scitranslmed.aay8329 [PubMed: 32051229]

Squires JE, Sun J, Caffrey JL, Yoshishige D, and Mallet RT (2003). Acetoacetate Augments β-adrenergic Inotropism of Stunned Myocardium by an Antioxidant Mechanism. Am. J. Physiology-Heart Circulatory Physiol 284, H1340–H1347. doi:10.1152/ajpheart.00473.2002

Stubbs BJ, Cox PJ, Evans RD, Cyranka M, Clarke K, and De Wet H (2018). A Ketone Ester Drink Lowers Human Ghrelin and Appetite. Obesity 26, 269–273. doi:10.1002/oby.22051 [PubMed: 29105987]

Stubbs BJ, Cox PJ, Evans RD, Santer P, Miller JJ, Faull OK, et al. (2017). On the Metabolism of Exogenous Ketones in Humans. Front. Physiol 8, 848. doi:10.3389/fphys.2017.00848 [PubMed: 29163194]

Sukhanov S, Higashi Y, Yoshida T, Mummidi S, Aroor AR, Jeffrey Russell J, et al. (2021). The SGLT2 Inhibitor Empagliflozin Attenuates Interleukin-17a-Induced Human Aortic Smooth Muscle Cell Proliferation and Migration by Targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 Secretion. Cell Signal. 77, 109825. doi:10.1016/j.cellsig.2020.109825 [PubMed: 33160017]

Sun Z, Chai Q, Zhang Z, Lu D, Meng Z, and Wu W (2021). Inhibition of SGLT1 Protects against Glycemic Variability-Induced Cardiac Damage and Pyroptosis of Cardiomyocytes in Diabetic Mice. Life Sci. 271, 119116. doi:10.1016/j.lfs.2021.119116 [PubMed: 33508297]

Szablewski L (2017). Glucose Transporters in Healthy Heart and in Cardiac Disease. Int. J. Cardiol 230, 70–75. doi:10.1016/j.ijcard.2016.12.083 [PubMed: 28034463]

Taegtmeyer H, Young ME, Lopaschuk GD, Abel ED, Brunengraber H, Darley-Usmar V, et al. (2016). Assessing Cardiac Metabolism: A Scientific Statement from the American Heart Association. Circ. Res 118, 1659–1701. doi:10.1161/res.0000000000000997 [PubMed: 27012580]

Taggart AKP, Kero J, Gan X, Cai T-Q, Cheng K, Ippolito M, et al. (2005). (d)-β-Hydroxybutyrate Inhibits Adipocyte Lipolysis via the Nicotinic Acid Receptor PUMA-G. J. Biol. Chem 280, 26649–26652. doi:10.1074/jbc.M500213200 [PubMed: 15929991]

Tahranii AA, Barnett AH, and Bailey CJ (2013). SGLT Inhibitors in Management of Diabetes. Lancet Diabetes Endocrinol. 1, 140–151. doi:10.1016/s2213-8587(13)70050-0 [PubMed: 24622320]

Taylor SI, Blau JE, and Rother CI (2015). SGLT2 Inhibitors May Predispose to Ketoacidosis. J. Clin. Endocrinol. Metab 100, 2849–2852. doi:10.1210/jc.2015-1884 [PubMed: 26086329]
Thai PN, Seidlmayer LK, Miller C, Ferrero M, Dorn GW, Saul S, et al. (2019). Mitochondrial Quality Control in Aging and Heart Failure: Influence of Ketone Bodies and Mitofusin-Stabilizing Peptides. Front. Physiol 10, 382. doi:10.3389/fphys.2019.00382 [PubMed: 31024341]

Thau-Zuchman O, Svendsen L, Dyall SC, Paredes-Esquivel U, Rhodes M, Priestley JV, et al. (2021). A New Ketogenic Formulation Improves Functional Outcome and Reduces Tissue Loss Following Traumatic Brain Injury in Adult Mice. Theranostics 11, 346–360. doi:10.7150/thno.48995 [PubMed: 33391479]

Tieu K, Perier C, Caspersen P, Wu D-C, Yan S-D, et al. (2003). D-β-Hydroxybutyrate Rescues Mitochondrial Respiration and Mitigates Features of Parkinson Disease. J. Clin. Invest 112, 892–901. doi:10.1172/jci200318797 [PubMed: 12975474]

Toldo S, and Abbate A (2018). The NLRP3 Inflammasome in Acute Myocardial Infarction. Nat. Rev. Cardiol 15, 203–214. doi:10.1038/nrcardio.2017.161 [PubMed: 29143812]

Tong Y, Wang Z, Cai L, Lin L, Liu J, and Cheng J (2020). NLRP3 Inflammasome and its Central Role in the Cardiovascular Diseases. Oxid Med. Cel Longev 2020, 4293206. doi:10.1155/2020/4293206

Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, et al. (2003). PUMA-G and HM74 Are Receptors for Nicotinic Acid and Mediate its Anti-lipolytic Effect. Nat. Med 9, 352–355. doi:10.1038/nm824 [PubMed: 12563315]

Uchihashi M, Hoshino A, Okawa Y, Arijoshi M, Kaimoto S, Tateishi S, et al. (2017). Cardiac-Specific Dbd1 Overexpression Ameliorates Oxidative Stress and Cardiac Remodeling in Pressure Overload-Induced Heart Failure. Circ Heart Fail 10, e004417. doi:10.1161/circheartfailure.117.004417 [PubMed: 29242353]

Van Hout GP, Bosch L, Ellenbroek GH, De Haan JJ, Van Solinge WW, Cooper MA, et al. (2017). The Selective NLRP3-Inflammasome Inhibitor MCC950 Reduces Infarct Size and Preserves Cardiac Function in a Pig Model of Myocardial Infarction. Eur. Heart J 38, 828–836. doi:10.1093/eurheartj/ehw247 [PubMed: 27432019]

Veech RL (2014). Ketone Ester Effects on Metabolism and Transcription. J. Lipid Res 55, 2004–2006. doi:10.1194/jlr.r046292 [PubMed: 24714648]

Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, et al. (2018). Empagliflozin Increases Cardiac Energy Production in Diabetes. JACC: Basic Translational Sci. 3, 575–587. doi:10.1016/j.jacbts.2018.07.006

Vickers SP, Cheetham S, Headland K, Dickinson K, Grempler R, Mayoux E, et al. (2014). Combination of the Sodium-Glucose Cotransporter-2 Inhibitor Empagliflozin with Orlistat or Sibutramine Further Improves the Body-Weight Reduction and Glucose Homeostasis of Obese Rats Fed a Cafeteria Diet. Diabetes. Metab. Syndro. Obes 7, 265–275. doi:10.2147/dmso.s58786

Wang D, Zhao M, Chen G, Cheng X, Han X, Lin S, et al. (2013). The Histone Deacetylase Inhibitor Vorinostat Prevents TNFα-Induced Necroptosis by Regulating Multiple Signaling Pathways. Apoptosis 18, 1348–1362. doi:10.1007/s10495-013-0866-y [PubMed: 23708756]

Wang L, Yang Z, Fan F, Sun S, Wu X, Lu H, et al. (2019). PHBHHx Facilitated the Residence, Survival and Stemness Maintain of Transplanted Neural Stem Cells in Traumatic Brain Injury Rats. Biomacromolecules 20, 3294–3302. doi:10.1021/acs.biomac.9b00408 [PubMed: 31251595]

Wang X, Liu J, Zhen J, Zhang C, Wan Q, Liu G, et al. (2014). Histone Deacetylase 4 Selectively Contributes to Podocyte Injury in Diabetic Nephropathy. Kidney Int. 86, 712–725. doi:10.1038/ki.2014.111 [PubMed: 24717296]

Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, et al. (2017). Fasting-mimicking Diet and Markers/risk Factors for Aging, Diabetes, Cancer, and Cardiovascular Disease. Sci. Transl Med 9, eaaI8700. doi:10.1126/scitranslmed.aai8700 [PubMed: 28202779]

Wende AR, Brahma MK, Mcginnis GR, and Young ME (2017). Metabolic Origins of Heart Failure. JACC: Basic Translational Sci. 2, 297–310. doi:10.1016/j.jacbts.2016.11.009

Whitworth AJ, and Pallanck LJ (2017). PINK1/Parkin Mitophagy and Neurodegeneration—What Do We Really Know In Vivo? Curr. Opin. Genet. Develop. 44, 47–53. doi:10.1016/j.gde.2017.01.016
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med 380, 347–357. doi:10.1056/nejmoa1812389 [PubMed: 30415602]

Wright EM, Loo DDF, and Hirayama BA (2011). Biology of Human Sodium Glucose Transporters. Physiol. Rev 91, 733–794. doi:10.1152/physrev.00055.2009 [PubMed: 21527736]

Xie M, Kong Y, Tan W, May H, Battiprolu PK, Pedrozo Z, et al. (2014). Histone Deacetylase Inhibition Blunts Ischemia/reperfusion Injury by Inducing Cardiomyocyte Autophagy. Circulation 129, 1139–1151. doi:10.1161/circulationaha.113.002416 [PubMed: 24396039]

Xie M, Tang Y, and Hill JA (2019). HDAC Inhibition as a Therapeutic Strategy in Myocardial Ischemia/reperfusion Injury. J. Mol. Cell Cardiol 129, 188–192. doi:10.1016/j.yjmcc.2019.02.013 [PubMed: 30825484]

Xie Z, Zhang D, Chung D, Tang Z, Huang H, Dai L, et al. (2016). Metabolic Regulation of Gene Expression by Histone Lysine β-Hydroxybutyrylation. Mol. Cell 62, 194–206. doi:10.1016/j.molcel.2016.03.036

Xu S, Tao H, Cao W, Cao L, Lin Y, Zhao SM, et al. (2021). Ketogenic Diets Inhibit Mitochondrial Biogenesis and Induce Cardiac Fibrosis. Signal. Transduct Target. Ther 6, 54. doi:10.1038/s41392-020-00411-4 [PubMed: 33558457]

Yamanashi T, Iwata M, Kamiya N, Tsunetomi K, Kajitani N, Wada N, et al. (2017). Beta-hydroxybutyrate, an Endogenic NLRP3 Inflammasome Inhibitor, Attenuates Stress-Induced Behavioral and Inflammatory Responses. Sci. Rep 7, 7677. doi:10.1038/s41598-017-08055-1 [PubMed: 28794421]

Yokokawa T, Sugano Y, Shimouchi A, Shibata A, Jinno N, Nagai T, et al. (2016). Exhaled Acetone Concentration Is Related to Hemodynamic Severity in Patients with Non-ischemic Chronic Heart Failure. Circ. J 80, 1178–1186. doi:10.1253/circj.cj-16-0011 [PubMed: 27026173]

Yokokawa T, Yoshihisa A, Kanno Y, Abe S, Misaka T, Yamada S, et al. (2019). Circulating Acetoacetate Is Associated with Poor Prognosis in Heart Failure Patients. JIC Heart & Vasculature 25, 100432. doi:10.1016/j.jicha.2019.100432 [PubMed: 31890860]

Youm Y-H, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. (2015). The Ketone Metabolite β-hydroxybutyrate Blocks NLRP3 Inflammasome-Mediated Inflammatory Disease. Nat. Med 21, 263–269. doi:10.1038/nm.3804 [PubMed: 25686106]

Yu Y, Yu Y, Zhang Y, Zhang Z, An W, and Zhao X (2018). Treatment with D-β-Hydroxybutyrate Protects Heart from Ischemia/reperfusion Injury in Mice. Eur. J. Pharmacol 829, 121–128. doi:10.1016/j.ejphar.2018.04.019 [PubMed: 29679541]

Yurista SR, Matsuura TR, Sillje HHW, Nijholt KT, Mcdaid KS, Shewale SV, et al. (2021). Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure. Circ. Heart Fail 14, e007684. doi:10.1161/circheartfailure.120.007684 [PubMed: 33356362]

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med 373, 2117–2128. doi:10.1056/nejmoa1504720 [PubMed: 26378978]

Zordoky BN, Sung MM, Ezekowitz J, Mandal R, Han B, Bjorndahl TC, et al. (2015). Metabonomic Fingerprint of Heart Failure with Preserved Ejection Fraction. PLoS One 10, e0124844. doi:10.1371/journal.pone.0124844 [PubMed: 26010610]

Zou Z, Sasaguri S, Rajesh KG, and Suzuki R (2002). dl-3-Hydroxybutyrate Administration Prevents Myocardial Damage after Coronary Occlusion in Rat Hearts. Am. J. Physiology-Heart Circulatory Physiol 283, H1968–H1974. doi:10.1152/ajpheart.00250.2002

Front Aging. Author manuscript; available in PMC 2022 March 18.
Figure 1. β-OHB levels under physiological and pathological conditions.
In a normal fed state, the circulating ketone body concentration is approximately 50 μM, and it can increase to 1-8 mM in neonates, during fasting, after prolonged exercise, and on a ketogenic diet. In pathological conditions like diabetic ketoacidosis, ketone body concentration can accumulate up to 20 mM.

β-OHB: β-hydroxybutyrate, SGLT2i: sodium-glucose cotransporter-2 inhibitors
Figure 2. A brief view of ketone body production and oxidation in the liver and heart.
Ketone bodies are mainly produced in the liver with fatty acid oxidation. After transported through circulation, β-OHB can be oxidized in extrahepatic organs like the heart. In the heart, β-OHB can generate acetyl-CoA and ATP via BDH1 and SCOT. SCOT is the rate-limiting enzyme of ketone body oxidation.

β-OHB: β-hydroxybutyrate, HMGCS: Hydroxymethylglutaryl-CoA synthase, BDH1: β-hydroxybutyrate dehydrogenase 1, SCOT: Succinyl-CoA:3-oxoacid-CoA transferase, ACAT: Acetyl-CoA acetyltransferase
Figure 3. The beneficial effects of β-OHB during cardiac stresses.
The concentration of β-OHB is increased after prolonged fasting, long-time exercise, exogenous supplementation, SGLT2i therapy, and heart failure. During the stress of heart failure and I/R injury, the utilization of β-OHB is increased (oxidative effect). In addition, as a ligand for GPR, an HDAC inhibitor, and an Nlrp3 inflammasome inhibitor, β-OHB protects the heart by enhancing autophagy and reducing inflammation and ROS production (non-oxidative effects).

β-OHB: β-hydroxybutyrate, SGLT2i: sodium-glucose cotransporter-2 inhibitors, Nlrp3: Nod-, LRR- and pyrin domain-containing protein 3, I/R: ischemia/reperfusion.